News coverage about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamis Pharmaceuticals Corporation earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.159553512728 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Adamis Pharmaceuticals Corporation (ADMP) Now Covered by Raymond James Financial, Inc. (americanbankingnews.com)
- Market Indicators For Your Reference – Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Stock Watch (stocksnewstimes.com)
- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Comprehensive Stock Analysis – The Investor Guide (wallstreetnews24.com)
- Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Is About To Breakout – Insider Financial (insiderfinancial.com)
- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – An Eye on Data – Stock Watch (stocksnewstimes.com)
Several research firms recently commented on ADMP. Raymond James Financial, Inc. began coverage on shares of Adamis Pharmaceuticals Corporation in a report on Tuesday. They issued an “outperform” rating and a $7.00 price target on the stock. Maxim Group restated a “buy” rating and issued a $13.00 price target on shares of Adamis Pharmaceuticals Corporation in a report on Monday, August 21st. Finally, ValuEngine upgraded shares of Adamis Pharmaceuticals Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $7.25.
Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) opened at 5.40 on Wednesday. Adamis Pharmaceuticals Corporation has a 1-year low of $2.40 and a 1-year high of $6.45. The stock’s 50 day moving average is $4.92 and its 200-day moving average is $4.51. The stock’s market cap is $169.30 million.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Adamis Pharmaceuticals Corporation (ADMP) Stock Price” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thestockobserver.com/2017/09/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-adamis-pharmaceuticals-corporation-admp-stock-price.html.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.